ARB Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about ARB clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 80 trials

Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Solid TumorsHGGCancer Harboring BRAF Alterations+1 more
Fore Biotherapeutics254 enrolled67 locationsNCT05503797
Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Head and Neck CarcinomaMalignant Solid NeoplasmSarcoma+59 more
Alliance for Clinical Trials in Oncology2,000 enrolled740 locationsNCT05334069
Recruiting
Phase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 1Phase 2

Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

ARBBVMDAutosomal-Dominant Bestrophinopathy+1 more
Opus Genetics, Inc10 enrolled4 locationsNCT07185256
Recruiting
Phase 1

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer104 enrolled10 locationsNCT06659341
Recruiting
Phase 4

Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB

Ceftazidime-avibactamAztreonamGram-negative Bacterial Infection+2 more
Jing Zhou144 enrolled1 locationNCT07478484
Recruiting

Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children

Carbapenem-Resistant Enterobacteriaceae Infection
Children's Hospital of Fudan University536 enrolled1 locationNCT04535661
Recruiting
Phase 1

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Avistone Biotechnology Co., Ltd.96 enrolled5 locationsNCT06716138
Recruiting
Phase 2

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Ann Arbor Stage II Follicular LymphomaGrade 1 Follicular LymphomaAnn Arbor Stage III Follicular Lymphoma+6 more
University of Washington20 enrolled1 locationNCT06442475
Recruiting
Phase 2

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Solid Tumors Harboring MET Amplification
AbbVie125 enrolled26 locationsNCT07196644
Recruiting
Phase 1

A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.120 enrolled1 locationNCT07189949
Recruiting

ARBOspot: Characterization of Arbovirus Specific T Cell Response in Patients by Using Enzyme Linked Immunospot (ELISpot) Assays

Arbovirus Infections
Fondazione IRCCS Policlinico San Matteo di Pavia500 enrolled1 locationNCT07291206
Recruiting

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
Bayer100 enrolled1 locationNCT04945330
Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Bayer150 enrolled76 locationsNCT04142437
Recruiting
Not Applicable

Comparison of Wound Healing for Diabetic Carbuncle Treated With Incision and Drainage Technique Using Cruciate Incision vs Saucerization Technique Both Followed by Vacuum Assisted Closure.

Carbuncle
King Edward Medical University124 enrolled1 locationNCT07428265
Recruiting
Phase 2

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma+1 more
M.D. Anderson Cancer Center31 enrolled1 locationNCT04745949
Recruiting
Phase 1Phase 2

A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.

Healthy ParticipantsSarbecovirus
SK Bioscience Co., Ltd.368 enrolled2 locationsNCT07280858
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities

Solid Tumors Harboring NTRK FusionNTRKNTRK Gene Fusion+1 more
Cullgen (Shanghai),Inc42 enrolled6 locationsNCT07394374
Recruiting
Not Applicable

PRP Plus Fractional CO₂ Laser for Acne Scars

Post-Acne Atrophic ScarsCarbon Dioxide LasersPlatelet-Rich Plasma
Gujranwala medical college District Headquarters Hospital, Gujranwala70 enrolled1 locationNCT07352215
Recruiting
Phase 1

A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation

Solid Tumors Harboring a TP53 Y220C Mutation
Changchun GeneScience Pharmaceutical Co., Ltd.82 enrolled1 locationNCT06908434